Opioid Measures

PQA Opioid Measures


The PQA has several opioid measures to address the opioid epidemic. Four measures evaluate use of opioids at high dosage (≥90 MME/day), from multiple prescribers and pharmacies, and concurrently with benzodiazepines; which are associated with an increased risk of potentially fatal opioid overdose. Three initial opioid prescribing measures evaluate new prescriptions at high dosage (≥50 morphine milligram equivalents per day), for long duration (>7 cumulative days’ supply), or for long-acting or extended release opioids, which are associated with an increased risk of chronic use, misuse, and in some cases, overdose. One measure evaluates annual drug monitoring among individuals prescribed long-term opioid therapy. Individuals with a cancer diagnosis, sickle cell disease, or those receiving hospice or palliative care are excluded.

  • Use of Opioids at High Dosage in Persons Without Cancer (OHD) (NQF #2940)
  • Use of Opioids from Multiple Providers in Persons Without Cancer (OMP) (NQF #2950)
  • Use of Opioids at High Dosage and from Multiple Providers in Persons Without Cancer (OHDMP) (NQF #2951)
  • Concurrent Use of Opioids and Benzodiazepines (COB) (#3389)
  • Initial Opioid Prescribing at High Dosage (IOP-HD)
  • Initial Opioid Prescribing for Long Duration (IOP-LD) (NQF #3558)
  • Initial Opioid Prescribing for Long-Acting or Extended-Release Opioids (IOP-LA)
  • Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO) (NQF #3451)
Ask about PQA Measures
PQA Opioid Core Measure Overview
Ask about PQA Measures
Learn More about the PQA Measure Development Process
Updated April 2022